A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92...

bPembrolizumab, an immunotherapy medication/b, significantly enhanced disease-free survival when added to the standard of care for patients with...

Researchers from The University of Texas MD Anderson Cancer Centre, USA, demonstrated that anti-PD-L1 immunotherapy in combination with...

Discover how pembrolizumab, an immunotherapy drug, enhances disease-free survival in advanced soft tissue sarcoma, offering a promising treatment...

Discover how pembrolizumab, an immunotherapy drug, enhances disease-free survival in advanced soft tissue sarcoma, offering a promising treatment...

Researchers at Winship Cancer Institute of Emory University have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a...

Glioblastoma is the most common – and the most malignant – primary brain tumour in adults. It’s aggressive and incurable. Even with treatment...

Using a gene signature technique to tailor chemotherapy for patients with early triple-negative breast cancer shows promise as a way to improve...

LOS ALTOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Immunotherapies that mobilise a patient’s immune system to fight cancer have become a treatment pillar. These therapies, including CAR T-cell...